In recognition of the immense potential of checkpoint inhibition in combating multiple cancers and the reality that immune-related adverse events (irAEs) pose a challenge that, if addressed, could lead to better overall outcomes for patients and broader use, the American Cancer Society and the Melanoma Research Alliance (MRA) have partnered to support research leading to the reduction of irAEs and the improvement of overall outcomes for cancer patients treated with checkpoint immunotherapy.
To that end, the two organizations have issued a Request for Applications for projects that test feasibility and generate preliminary data. MRA and ACS have each committed $1 million for the awards. The combined $2 million will be used to fund Multidisciplinary Team Awards and Pilot Awards.
1) Multidisciplinary Team Awards: At least one grant of up to $1 million will be awarded in this category to foster interdisciplinary collaborative research and promote transformational advances with the potential for rapid clinical benefit. Letters of Intent must be received no later than August. Upon review, selected applicants will be invited to submit a full application by October 31, 2017.
2) Pilot Awards: Up to five grants of up to $200,000 each will be awarded over two years to help seed the ground in this relatively young area of checkpoint irAE research. Applications must be received no later than October 16, 2017.
Both categories are designed to support research on the prevention, early detection, reduction, and/or management of life-altering and/or outcome-limiting side-effects of checkpoint inhibitor therapy. Projects should focus on research leading to mitigation of irAEs while preserving or enhancing checkpoint blockade effectiveness. Research topics of interest include but are not limited to the biological basis and mechanism of irAEs; prevention of irAEs; detection and biomarkers; measurement of symptom clusters; and clinical translation of research.
See the ACS website for complete program guidelines and application instructions.